Quantitative Immunofluorescence Evaluation of PD-L1 Expression in Non-Muscle-Invasive and Muscle-Invasive Urothelial Bladder Cancer

Richters, A., Aben, K.K.H., and Kiemeney, L.A.L.M., World J. Urol., 2020, vol. 38, no. 8, p. 1895.

Article  PubMed  Google Scholar 

Patel, V.G., Oh, W.K., and Galsky, M.D., CA Cancer J. Clin., 2020, vol. 70, no. 5, p. 404.

Article  PubMed  Google Scholar 

Unsworth-White, S.R., Kitchen, M.O., and Bryan, R.T., Future Oncol., 2022, vol. 18, no. 1, p. 105.

Article  CAS  PubMed  Google Scholar 

Nemtsova, M.V. and Kushlinskii, N.E., Al’manakh Klin. Med., 2015, no. 41, p. 79.

Ministry of Health of the Russian Federation. Clinical guidelines on bladder cancer, 2021. https://cr.minzdrav.gov.ru/schema/11_2. Accessed February 27, 2023.

Patel, S.P. and Kurzrock, R., Mol. Cancer Ther., 2015, vol. 14, no. 4, p. 847.

Article  CAS  PubMed  Google Scholar 

Bogush, T.A., Basharina, A.A., Eliseeva, B.K., Kaliuzhny, S.A., Bogush, E.A., Kirsanov, V.Y., Davydov, M.M., and Kosorukov, V.S., BioTechniques, 2020, vol. 69, no. 4, p. 257.

Article  CAS  PubMed  Google Scholar 

Szabados, B., Kockx, M., Assaf, Z.J., van Dam, P.J., Rodriguez-Vida, A., Duran, I., Crabb, S.J., van der Heijden, M.S., Pous, A.F., Gravis, G., Herranz, U.A., Protheroe, A., Ravaud, A., Maillet, D., Mendez, M.J., Suarez, C., Linch, M., Prendergast, A., Tyson, C., Stanoeva, D., Daelemans, S., Rombouts, M., Mariathasan, S., Tea, J.S., Mousa, K., Sharma, S., Aleshin, A., Banchereau, R., Castellano, D., and Powles, T., Eur. Urol., 2022, vol. 82, no. 2, p. 212.

Article  CAS  PubMed  Google Scholar 

Joshi, M., Tuanquin, L., Zhu, J., Walter, V., Schell, T., Kaag, M., Kilari, D., Liao, J., Holder, S.L., Emamekhoo, H., Sankin, A., Merrill, S., Zheng, H., Warrick, J., Hauke, R., Gartrel, B., Stein, M., Drabick, J., Degraff, D.J., and Zakharia, Y., J. Immunother. Cancer, 2023, vol. 11, no. 2, p. e006551.

Article  PubMed  PubMed Central  Google Scholar 

Cathomas, R., Lorch, A., Bruins, H.M., Comperat, E.M., Cowan, N.C., Efstathiou, J.A., Fietkau, R., Gakis, G., Hernandez, V., Espinos, E.L., Neuzillet, Y., Ribal, M.J., Rouanne, M., Thalmann, G.N., van der Heijden, A.G., Veskimae, E., Alfred Witjes, J., and Milowsky, M.I., Eur. Urol., 2022, vol. 81, no. 1, p. 95.

Article  PubMed  Google Scholar 

Atezolizumab and BCG in high risk BCG naïve non-muscle invasive bladder cancer (Nmibc) Patients (Bladdergate). https://clinicaltrials.gov/ct2/show/ NCT04134000?term=PD-L1&cond=Non-muscle-in vasive+Bladder+Cancer&draw=2&rank=5. Accessed March 1, 2023.

Assessment of efficacy and safety of Durvalumab Plus BCG compared to the standard therapy with BCG in non-muscle invasive bladder cancer (POTOMAC). https://clinicaltrials.gov/ct2/show/NCT03528694? term=PD-L1&cond=Non-muscle-in vasive+Bladder+ Cancer&draw=2&rank=10. Accessed March 1, 2023.

A study of Sasanlimab in people with non-muscle invasive bladder cancer (CREST). https://clinicaltrials.gov/ct2/show/NCT04165317?term=PD-L1&cond= Nonmuscle-invasive+Bladder+Cancer&draw=2&rank =4. Accessed March 1, 2023.

留言 (0)

沒有登入
gif